Table 2 Clinical management according to gender status
Whole cohort (n = 793) | Male (n = 571) | Female (n = 222) | P value | |
|---|---|---|---|---|
Vasoactive drugs | ||||
Dobutamine | 716 (90.3) | 530 (92.8) | 186 (83.8) | 0.001 |
Dopamine | 62 (7.8) | 42 (7.4) | 20 (9) | 0.435 |
Adrenaline | 132 (16.6) | 95 (16.6) | 37 (16.7) | 0.992 |
Noradrenaline | 620 (78.2) | 444 (77.8) | 176 (79.3) | 0.436 |
Levosimendan | 75 (9.5) | 59 (10.3) | 16 (7.2) | 0.177 |
Milrinone | 16 (2) | 6 (1.1) | 10 (4.5) | 0.004 |
Invasive procedures | ||||
Renal replacement therapy | 150 (19) | 105 (18.5) | 45 (20.3) | 0.558 |
Invasive mechanical ventilation | 489 (61.7) | 358 (62.7) | 131 (59) | 0.617 |
Non invasive mechanical ventilation | 77 (9.7) | 53 (9.3) | 24 (10.8) | 0.597 |
Therapeutic hypothermia | 43 (5.4) | 35 (6.1) | 8 (3.6) | 0.158 |
Swan-Ganz catheter | 273 (34.4) | 191 (33.5) | 82 (36.9) | 0.353 |
Intraaortic counterpulsation | 370 (46.7) | 274 (48) | 96 (43.2) | 0.229 |
ECMO | 67 (8.4) | 53 (9.3) | 14 (6.3) | 0.176 |
Impella® | 30 (3.8) | 23 (4) | 7 (3.2) | 0.562 |
Levitronix centrimag® | 55 (6.9) | 40 (7) | 15 (6.8) | 0.902 |
Revascularization | 0.426 | |||
None | 334 (42.1) | 233 (40.8) | 101 (45.5) | |
PCI | 433 (54.6) | 320 (56) | 113 (50.9) | |
Surgical | 26 (3.3) | 18 (3.2) | 8 (3.6) | |